Drug Search Results
More Filters [+]

Semaglutide

Alternative Names: semaglutide, rybelsus, ozempic, wegovy
Latest Update: 2024-10-14
Latest Update Note: Clinical Trial Update

Product Description

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34305810/)

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Oral,Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States

Approved Indications: Pancreatitis | Type 1 Diabetes | General Diabetes | Type 2 Diabetes | Hypertension | Pancreatitis | Pancreatitis, Chronic | Dyslipidemia | General Diabetes | Type 2 Diabetes | Obesity | Obesity, Morbid | Overweight | Weight Loss

Known Adverse Events: Abdominal Pain | Pain Unspecified | Constipation | Diarrhea | Dizziness | Headache | Enteritis | Gastroenteritis | Gastroesophageal Reflux | General Diabetes | Hypoglycemia | Type 2 Diabetes | Dyspepsia | Eructation | Flatulence

Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Semaglutide

Countries in Clinic: Algeria, Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Latvia, Lebanon, Malaysia, Mexico, Morocco, Netherlands, New Zealand, North Macedonia, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 164

Highest Development Phases

Phase 3: Albuminuria|Alzheimer Disease|Diabetes, Gestational|Diabetic Retinopathy|Fatty Liver, Alcoholic|Glucose Intolerance|Heart Failure|Heart Failure, Chronic|Heart Failure, Diastolic|Hepatitis, Alcoholic|Intermittent Claudication|Kidney Diseases|Kidney Failure, Chronic|Non-alcoholic Steatohepatitis|Obesity|Obesity, Morbid|Osteoarthritis, Knee|Overweight|Peripheral Arterial Disease|Peripheral Vascular Diseases|Prediabetic State|Schizophrenia|Stomach Diseases|Stroke|Type 2 Diabetes|Weight Gain|Weight Loss

Phase 2: Diabetic Nephropathy|Endometrial Hyperplasia|Inflammation|Mucositis|Prediabetes|Type 1 Diabetes

Phase 1: Healthy Volunteers|Hypercholesterolemia|Myocardial Infarction|Pain Unspecified|Polycystic Ovary Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT05829460

P2

Not yet recruiting

Endometrial Hyperplasia

2029-10-31

ESSENCE

P3

Active, not recruiting

Hepatitis, Alcoholic|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis

2029-04-25

NN9931-4553

P3

Unknown Status

Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic

2029-04-25

ESSENCE

P3

Active, not recruiting

Non-alcoholic Steatohepatitis|Hepatitis, Alcoholic

2028-07-28

Recent News Events